Cocrystal Pharma Stock Current Valuation
| COCP Stock | USD 2.07 0.04 1.90% |
Valuation analysis of Cocrystal Pharma helps investors to measure Cocrystal Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Cocrystal Pharma's Enterprise Value Over EBITDA is relatively stable compared to the past year. As of 12/03/2024, Enterprise Value Multiple is likely to grow to 0.43, while Enterprise Value is likely to drop slightly above 88.5 M. Fundamental drivers impacting Cocrystal Pharma's valuation include:
Price Book 1.6378 | Enterprise Value 9.7 M | Enterprise Value Ebitda 0.661 | Price Sales 92.4548 | Enterprise Value Revenue 17.8912 |
Undervalued
Today
Please note that Cocrystal Pharma's price fluctuation is risky at this time. Calculation of the real value of Cocrystal Pharma is based on 3 months time horizon. Increasing Cocrystal Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cocrystal Pharma's intrinsic value may or may not be the same as its current market price of 2.07, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.07 | Real 3.87 | Target 9.67 | Hype 2.06 | Naive 2.17 |
The intrinsic value of Cocrystal Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cocrystal Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cocrystal Pharma helps investors to forecast how Cocrystal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cocrystal Pharma more accurately as focusing exclusively on Cocrystal Pharma's fundamentals will not take into account other important factors: Cocrystal Pharma Company Current Valuation Analysis
Cocrystal Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cocrystal Pharma Current Valuation | 9.66 M |
Most of Cocrystal Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cocrystal Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cocrystal Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Cocrystal Pharma is extremely important. It helps to project a fair market value of Cocrystal Stock properly, considering its historical fundamentals such as Current Valuation. Since Cocrystal Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cocrystal Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cocrystal Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Cocrystal Current Valuation Historical Pattern
Today, most investors in Cocrystal Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cocrystal Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cocrystal Pharma current valuation as a starting point in their analysis.
Cocrystal Pharma Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cocrystal Pharma has a Current Valuation of 9.66 M. This is 99.93% lower than that of the Pharmaceuticals sector and 99.79% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Cocrystal Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cocrystal Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cocrystal Pharma could also be used in its relative valuation, which is a method of valuing Cocrystal Pharma by comparing valuation metrics of similar companies.Cocrystal Pharma is currently under evaluation in current valuation category among its peers.
Cocrystal Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cocrystal Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cocrystal Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Cocrystal Fundamentals
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 9.66 M | ||||
| Shares Outstanding | 10.17 M | ||||
| Shares Owned By Insiders | 31.85 % | ||||
| Shares Owned By Institutions | 6.94 % | ||||
| Number Of Shares Shorted | 8.01 K | ||||
| Price To Earning | 193.33 X | ||||
| Price To Book | 1.64 X | ||||
| Price To Sales | 92.45 X | ||||
| Gross Profit | (8.79 M) | ||||
| EBITDA | (19.37 M) | ||||
| Net Income | (17.98 M) | ||||
| Cash And Equivalents | 51.03 M | ||||
| Cash Per Share | 6.28 X | ||||
| Total Debt | 1.85 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 18.34 X | ||||
| Book Value Per Share | 2.59 X | ||||
| Cash Flow From Operations | (14.67 M) | ||||
| Short Ratio | 0.12 X | ||||
| Earnings Per Share | (1.82) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 20.81 M | ||||
| Total Asset | 31.26 M | ||||
| Retained Earnings | (315.91 M) | ||||
| Working Capital | 25.83 M | ||||
| Current Asset | 6.75 M | ||||
| Current Liabilities | 3.15 M | ||||
| Net Asset | 31.26 M |
About Cocrystal Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cocrystal Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cocrystal Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cocrystal Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cocrystal Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Cocrystal Stock
| 0.68 | EYEN | Eyenovia | PairCorr |
| 0.53 | ENVB | Enveric Biosciences | PairCorr |
| 0.52 | A | Agilent Technologies | PairCorr |
| 0.48 | FATE | Fate Therapeutics | PairCorr |
| 0.47 | VRPX | Virpax Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.